Werkgroep Cardiologische centra Nederland English

VICTORIA (Follow up)

A randomized parallel-group, placebo-controlled, double-blind, event-driven, multicenter pivotal phase III clinical outcome trial of efficacy and safety of the oral sGC stimulator vericiguat (BAY 1021189) in patients with heart failure and reduced ejection fraction (HFrEF) - VerICiguaT glObal study in patients with HF and Reduced ejectIon frAction (VICTORIA)

Middel
Vericiguat
Populatie
hartfalen
Fase
III
Jaar aanvang
2016
Meer informatie
ClinicalTrials.gov